Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial.
Publication/Presentation Date
6-1-2022
Abstract
The purpose of this work was to use data from a large co-operative group trial to evaluate whether metabolic FDG-PET changes in the heart for lung cancer patients can predict for clinical outcomes. The study found that cardiac SUV changes following definitive chemoradiation are significantly (HR 0.811, 95% CI 0.68-0.96, p = 0.017) associated with overall survival in locally advanced NSCLC patients. If validated in a prospective cohort, our data show the potential for cardiac metabolic changes to be an early predictor for clinical outcomes.
Volume
171
First Page
22
Last Page
24
ISSN
1879-0887
Published In/Presented At
Miller, R., Santangelo, T., Forghani-Arani, F., Rusthoven, C., Chen, Y., Castillo, E., Castillo, R., Guerrero, T., & Vinogradskiy, Y. (2022). Changes in post-treatment cardiac PET avidity predict overall survival in lung cancer patients treated with chemoradiation: Secondary analysis of the ACRIN 6668/RTOG 0235 clinical trial. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 171, 22–24. https://doi.org/10.1016/j.radonc.2022.04.003
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35413391
Department(s)
Administration and Leadership
Document Type
Article